Five out of six patients in Roche’s study testing its weight-loss drug CT-996 suffered nausea. One in six had “chronic reflux” and two vomited. These side effects of the drug are hurting the Swiss company’s stock market, with falls that reached 6.75% on the American market this Wednesday.
With these results, the company stands out from the competition that has appeared in the sector in recent months to cover the need to lose weight. As explained by Bloomberg, Estimates indicate a market that will reach $130 billion in revenue by the end of the decade.and will face a growing health problem such as obesity.
Manu Chakravarthy, global head of product development for the company’s cardiovascular, renal and metabolic division, is undeterred by the trial results, calling them “encouraging.” The company is reportedly preparing for clinical trials with larger sample sizes, and Chakravarthy says, “the purpose of doing these phase 1 studies is to push the doses, to understand where the limits of tolerance are.”
